Comment on

• A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.

  Lopez Bernaldo de Quiros JC, Miro JM, Peña JM, Podzamczer D, Alberdi JC, Martínez E, Cosin J, Claramonte X, Gonzalez J, Domingo P, Casado JL, Ribera E; Grupo de Estudio del SIDA 04/98. Lopez Bernaldo de Quiros JC, et al. N Engl J Med. 2001 Jan 18;344(3):159-67. doi: 10.1056/NEJM200101183440301. N Engl J Med. 2001. PMID: 11172138 Clinical Trial.
• Discontinuing Pneumocystis carinii prophylaxis.

  Girard PM. Girard PM. N Engl J Med. 2001 Jan 18;344(3):222-3. doi: 10.1056/NEJM200101183440310. N Engl J Med. 2001. PMID: 11172146 No abstract available.
• Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.

  Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, D'Arminio Monforte A, Schneider MM, Lundgren JD; Eight European Study Groups. Ledergerber B, et al. N Engl J Med. 2001 Jan 18;344(3):168-74. doi: 10.1056/NEJM200101183440302. N Engl J Med. 2001. PMID: 11188837